Meeting
2015 Gastrointestinal Cancers Symposium
Evaluation of α-1-acid glycoprotein as a prognostic factor of survival in patients with stage II-III esophageal carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil chemotherapy followed by surgery.
Authors
Yusuke Sasaki
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
Yusuke Sasaki , Ken Kato , Koh Furuta , Naoki Takahashi , Hirokazu Shoji , Yoshitaka Honma , Satoru Iwasa , Natsuko T. Okita , Atsuo Takashima , Tetsuya Hamaguchi , Yasuhide Yamada , Narikazu Boku
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 100)
DOI
10.1200/jco.2015.33.3_suppl.100
Abstract #
100
Poster Bd #
B50
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Loss of body weight during neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil as predictive of poor survival of patients with esophageal squamous cell carcinoma.
First Author: Munehiro Ito
Poster
2013 Gastrointestinal Cancers Symposium
Neoadjuvant DCF in resectable esophageal cancer: Single-center experience.
First Author: Vanita Noronha
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of prophylactic pegfilgrastim on day 3 of neoadjuvant DCF chemotherapy in elderly patients with resectable esophageal cancer.
First Author: Go Ikeda
Poster
2022 ASCO Annual Meeting
Phase 3 randomized study comparing docetaxel-platinum with docetaxel-platinum-5 fluorouracil as neoadjuvant chemotherapy in technically unresectable oral cancer.
First Author: Ajaykumar Singh